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Analysis of HLA class II transgenic mice has progressed in recent years from analysis of single 
chain HLA class II transgenes with expression of mixed mouse/human heterodimers to double 
transgenic mice expressing normal human heterodimers. Previous studies have used either HLA 
transgenic mice in which there is a species-matched interaction  with CD4 or mice which lack 
this interaction. Since both systems are reported to generate HLA-restricted responses, the matter 
of the requirement for species-matched CD4 remains unclear. We have generated triple transgenic 
mice expressing three human transgenes, DRA, DRB, and CD4, and compared HLA-restricted 
responses to peptide between human-CD4 + (Hu-CD4 +) and Hu-CD4-  littermates.  We saw 
no difference between Hu-CD4 + and Hu-CD4-  groups, supporting the notion that for some 
responses at least the requirement for species-matched CD4 may not be absolute. Evidence for 
positive selection of mouse T cell receptors in HLA-DR transgenic mice came both from the 
acquisition of new, HLA-restricted responses to various peptides and from an increased frequency 
of T cells using the TCR V34 gene segment.  An important goal with respect to the analysis 
of function in HLA transgenic  mice is the clarification of mechanisms which underpin the 
recognition of self-antigens in human autoimmune disease. As a first step towards 'humanized' 
disease models in HLA transgenic mice, we analyzed the responses of HLA-DR transgenic mice 
to the human MPB 139-154 peptide which has been implicated as an epitope recognized by T 
cells of multiple sclerosis patients.  We obtained T cell responses to this epitope in transgenic 
mice but not in nontransgenic controls.  This study suggests that HLA transgenic mice will 
be valuable in the analysis of HLA-restricted T  cell epitopes implicated in human disease and 
possibly in the design of new disease models. 
T 
he mapping of patterns of MHC restriction,  epitope 
recognition and T cell effector function in the murine 
immune response  has  generally  been  determined by  ex- 
perimental in vivo priming. Analysis  of human T cell responses 
has necessarily involved a different approach: lines and clones 
derived from natural priming have been analyzed in vitro, 
assessing HLA-restriction for example using various means 
including antibody blocking and B-lymphoblastoid cell lines 
(BLCL)  1 or HLA transfectants  as antigen presenting  cells. 
These approaches, though valuable, have left functional ques- 
tions such as the in vivo effector activity of human clones 
of particular specificities or the functional basis for HLA as- 
sociations with autoimmune disease  difficult to confront. The 
generation of HLA transgenic mice (as well as complemen- 
t Abbreviations used in this  paper: B-LCL, B-lymphoblastoid cell lines; DE 
double positive; MBE myelin basic protein;  MS, multiple sclerosis. 
tary human TCK transgenic mice) has therefore been an im- 
portant step towards the creation of in vivo models for the 
functions  of human molecules. 
HLA class I transgenic mice have been available for some 
years and have allowed the analysis  of  HLA-restricted responses 
with variable success. HLA-B27/32m double transgenic mice 
were shown to make HLA-restricted responses to influenza 
virus and Sendai virus (1, 2). When expressed in transgenic 
rats at high copy number, HLA-B27 was associated with a 
disease phenotype reminiscent  of the B27-associated spon- 
dyloarthropathies, although the role of HLA-restricted T cells 
in pathogenesis is unknown (3, 4). However, mice transgenic 
for a number of HLA class I transgenes did not have  demon- 
strable HLA-restricted T cells at significant frequencies and 
did not recognize HLA-disparate cells at a higher frequency 
than the normal, low level  of murine xenoreactivity to human 
targets (5, 6). This could have  been attributable either to some 
structural  constraint on positive selection of mouse T  cell 
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for a species-matched interaction between CD8  and class I 
in order for T  cell activation to occur. The latter proposal 
is supported by the finding that there is strong recognition 
by mouse T cells of transgenic cells carrying chimaeric mole- 
cules where a species-matched class I/CD8 interaction is re- 
stored by splicing the murine c~3 domain into a human class 
I  molecule (7). 
With respect to HLA class  II transgenic mice, a number 
of laboratories including ours showed that single human class 
II cr  or B chains expressed from transgenes could pair with 
murine partner chains to give a functional molecule capable 
of inducing positive or negative selection of mouse T  cell 
receptors (8-12). One laboratory has produced data showing 
that  HLA-DR  and  DQ  transgenic  lines  can  make  HLA- 
restricted responses to various antigens in the absence of a 
Hu-CD4 molecule (13, 14). Nevertheless, the extent to which 
murine CD4 can interact with HLA class II molecules has 
remained a  contentious  issue (15-17). 
We here report HLA-DR1 transgenic mice made with rel- 
atively large fragments of genomic sequence to retain faithful 
tissue expression of the molecule in mice which either have 
or lack a human CD4 transgene.  The mice have been used 
to investigate responsiveness to various antigenic peptides in- 
cluding, as a step towards the analysis of HLA class II trans- 
genic disease models, a human myelin basic protein (MBP) 
epitope commonly recognized by multiple sclerosis (MS) pa- 
tients  (18,  19). 
Materials  and Methods 
Transgenic Lines.  HLA-DR1 transgenic mice were generated 
by coinjection of inserts from two cosmid clones, MANN 4.2 which 
carries  the full HLA-DRAI*0101  gene and  several kilobases  of 
flanking sequence  (20) and pWE15DR1B1 which carries the full 
HLA-DRB1 *0101 gene and several kilobases of flanking sequence. 
Expression  of the former construct has previously been described 
by us (11, 12) and the potential for expression of the DRB cosmid 
was confirmed by cotransfection with DRA into mouse L cells 
(H. Inoko, unpublished observations). Transgenic mice were gener- 
ated by coinjection of the DRA gene as a 24-kb BamHI fragment 
and of a 22-kb NotI fragment carrying the DRB gene into fertil- 
ized FVB/N  oocytes (21).  The work reported here is based  on 
progeny from one of the founders which was found to have coin- 
tegrated multiple copies of the two transgenes.  HLA transgenic 
mice were initially characterized by Southern hybridization of 
BamHI-digested genomic DNA to a DRB cDNA probe. To do 
this, 20 #g of tail DNA was digested to completion with BamHI, 
run on an agarose gel and blotted onto Hybond-N (Amersham 
International, Amersham, UK), before hybridizing to a 510-bp DRB 
5' cDNA probe at 65~  then washing at high stringency.  Blots 
were exposed to XAR-5 film overnight. Hu-CD4 transgenic mice 
have previously been described (22). Briefly, they were generated 
with a construct whereby a full-length cDNA for the human CD4 
molecule is under the control of a mouse class I H-2K promoter. 
Once lines had been established the identity of transgenic animals 
among progeny was assessed by PCR.  For HLA-DR we used a 
pair of primers corresponding to amino acid residues  18-24 and 
84-93 of HLA-DRBI*0101  (sense primer: TTC TTC AAC GGG 
ACG GAG CGG GTG; antisense  primer: CTG CAC TGT GAA 
GCT CTC ACC AAC). Cosegregation of the DRA transgene was 
initially checked by hybridization of a  DRcr  cDNA  probe  to 
Southern filters of genomic DNA and thereafter by PCR with the 
following DRA primers.  Sense: the primer pair used for detection 
of human CD4 was sense primer: AGG CCT CCA GCA TAGT; 
anti-sense  primer: CCT GAT GCA ACT TTC CTG. Mice were 
maintained as hemizygotes to allow functional comparison of trans- 
gene positive and negative mice from individual litters. 
Flow Cytoraetry.  Splenocytes  were resuspended in phosphate- 
buffered saline containing 0.5% BSA and incubated on ice in the 
presence of a saturating concentration (25/zg/ml) of the following 
mAbs which were used as affinity purified and biotinylated IgG: 
L243 (anti-DRew) (23), TDR31.1 (anti-DRB) (24), TAL 14.1 (anti- 
DR,8)  (25,  26), M5/114.15.2  (anti-H-2A),  Leu 3a (anti-human 
CD4), and KT174 (anti-mouse CD4). Pbycoerythrin (PE)-strep- 
tavidin (Becton Dickinson, Cowley, UK) was used as the second 
layer. 8,000 events were analyzed for each sample  on a FACScan 
(Becton Dickinson). For three-color analysis of CD4+8 § double 
positive (DP) thymocytes, cells were stained with anti-mouse CD4- 
PE (CALTAG Labs., South San Francisco, CA), KT15 anti-mouse 
CDS-FITC and biotinylated Leu 3a, with streptavidin-tricolor as 
second layer. Cells were tightly gated on mouse CD4+CD8 + DP's 
(FL1 and FL2) and these cells were then analyzed for FL3 fluores- 
cence. For the evaluation of the percentage ofT cells bearing specific 
VB chains,  106 mesenteric lymph node cells from 3-too-old mice 
were incubated for 45 min at 4~  with FITC-conjugated anti-CD4 
(KT6) and anti-CD8 (KT15), and biotinylated anti-V~ antibodies 
(V/~3, KJ25 [27]); V~4, KT4 [28]), V~8.1,2,3,  F23.1 [29]; V~5.2, 
MR9.8 [30]; VB13, MR12-4 [31]; and V810, B20.5 [12]), washed 
three times and incubated for 20 min at 4~  with PE-streptavidin 
(Becton Dickinson). Cells were analyzed on a FACScan using LYSIS 
II software and gated for live cells on the basis of forward and side 
scatter. The CD4 § and CD8 § populations were separated on the 
FL1 axis by virtue of their relative brightness and could then be 
gated for statistical  analysis of V~ staining in each compartment. 
Statistical  significance  was calculated  by Student's t test. 
Imraunocytockemistry.  Frozen sections  of transgenic and non- 
transgenic mouse thymus were fixed with acetone and stained with 
biotinylated L243 (anti-DRc~) or TAL 14.1 (anti-DR,8).  They were 
probed with streptavidin-horseradish  peroxidase (Dako Corp., Car- 
pinteria, CA), developed with diaminobenzidine (Dako) and coun- 
terstained with Mayer's  hematoxylin (Sigma  Chemical Co.,  St. 
Louis, MO). 
T Cell Proliferation Assays.  Young adult, age, and sex-matched 
mice were primed in each hind footpad with 50 #g of each of the 
indicated antigenic peptides in complete Freund's adjuvant. 8 d later 
(except where indicated otherwise) popliteal lymph node cells were 
removed and assayed for T cell proliferation at 4  x  10  s cells/flat- 
bottom well.  Plates  were cultured for 72 h  in HL1 serum-free 
medium (New Brunswick Scientific Ltd, Hatfield, UK) containing 
penicillin, streptomycin, glutamine, and 2-mercaptoethanol. Wells 
were pulsed for the final 6 b  with  1 /~ci [3H]thymidine before 
being harvested onto filtermats for liquid scintillation counting in 
an LKB Betaplate counter. Unless stated otherwise, results are ex- 
pressed as the Acpm of the mean from cultures with antigen minus 
the mean from cultures without antigen, where background counts 
in the absence of antigen were always less than  1,000 cpm. 
Generation ofT Cell Lines.  Popliteal lymph node cells from HA 
307-319 immunized HLA-DR1 transgenic mice were removed at 
day 11 after immunization and cultured at 2  x  106 cells/ml in 12- 
well plate (Costar Corp., Cambridge, MA). After a further 10 d 
they  were  restimulated  using  irradiated  HLA-DR1 +  mouse 
splenocytes and peptide at 50 ~g/ml. 3 d after restimulation the 
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cycle of restimulation was repeated a further three times. Lines were 
tested against a panel of  APC 8-10 d after the previous restimulation. 
Antigen Presenting Cell Lines for Analyzing HLA  Restriction of 
T Cell Lines.  Various cell lines were tested for antigen presentation 
to T cell lines, using 4  x  10  s APC plus 1  x  104 line T  cells per 
well. The human B cell lines PGF (DRw15 homozygous B-LCL), 
HOM-2 (DR.1Dwl homozygous B-LCL), and the class II null mu- 
tant, ILJ2.2.5 were all maintained in P,.PMI 1640 supplemented with 
10% FCS penicillin, streptomycin, and glutamine.  Mock-transfected 
(vector only) mouse L cells and their DILl-transfected counterpart 
(26)  were  grown  in  Dulbecco's modified Eagle's  medium  sup- 
plemented with 10% FCS penicillin,  streptomycin, glutamine, and 
500/~g/ml Hygromycin B (Calbiochem-Novabiochem Corp., La 
Jolla, CA).  All APC were treated with 40/zg/ml  mitomycin c 
(Sigma) at 37  ~ for 40 min before washing and adding to microtitre 
plates. T cell line/APC assays were conducted in HL1 medium for 
72 h  as described above. 
II.  The strong band to which  the DR/3 cDNA  hybridizes 
is the •4-kb  BamHI genomic fragment carrying exons 2 and 
3  of DRB.  All mice which were positive for this band by 
Southern blotting  were also found  to be positive by PCK 
for both DRB  and DRA.  The human CD4 transgene was 
crossed  onto  HLA-DK1  transgenic  from  an  independent 
founder and so segregated independently of the DR  trans- 
genes in crosses between the two transgenic lines. PCK anal- 
ysis  of the CD4  transgene  is  shown  in  Fig.  1  b. 
When tissues from HLA-DR transgenic mice were ana- 
lyzed for HLA-DR  mtLNA by Northern analysis,  we ob- 
tained the result previously reported (11); HLA-DK mKNA 
was expressed in spleen, lymph node and thymus with a very 
small amount of transcript in kidney and lung while brain, 
heart,  and  testis were negative (data not  shown).  We then 
analyzed surface expression of the human heterodimer on FACS 
(Fig. 2). Splenocytes of triple transgenic mice or non-transgenic 
Results 
Characterization  of  HLA-DR1  Transgenic Mice.  Mice were 
initially characterized by Southern hybridization of BamHI- 
digested genomic DNA  to DRA  and DRB cDNA probes. 
Fig.  I  a shows an example of this analysis with a transgenic 
mouse shown in track A and human genomic DNA in track 
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Figure  1.  Genotyping of transgenic mice. (a) Southern analysis of 
genomic DNA from an HLA-DR + litter hybridized  with a DRB cDNA 
probe. Lanes  A-F are offspring from the litter where A shows a positive 
mouse. Lane G, non-transgenic mouse negative control; lane H, human 
genomic DNA positive  control. (b) PCR analysis of the same litter using 
PCR primers for human CD4. The tracks are as in a. 
Figure  2.  FACS  analysis  ofsplenoeytes  from HLA-DR/Hu-CD4 trans- 
genic  mice. In each  panel, staining  of  cells  from a triple-transgenic  is shown 
by the stippled histogram and of cells from a negative littermate by the 
unshaded histogram. The x axis shows log FL-2  brightness and the y axis 
cell number. The bar marked M1 in each case shows the population of 
cells with specific  fluorescence  brighter than obtained when an isotype- 
matched irrelevant first layer  was used. The antibodies are as follows:  A, 
L243 (DRa); B, TDR 31.1 (DR/3); C, TAL 14.1 (DRB); D, M5/114.15.2 
(H-2A); E, KT174 (Mu-CD4); F, Leu 3a (Hu-CD4). 
869  Altmann et al. littermates were stained with mAbs against HLA-DR  and 
CD4.  One  mAb  against  DRot  (L243,  panel A)  and  two 
different mAbs against non-polymorphic epitopes on DRB 
(TDR31.1 and TAL, 14.1, panels B and C) each showed clear 
staining of a distinct, brightly stained sub-population of cells. 
Expression was comparable with the brightness of staining 
obtained using the anti-H-2A mAb M5/114.15.2 (panel D). 
In some experiments lymph node cells or peripheral blood 
were stained and also  found to be strongly positive for the 
transgenes (data not shown).  No cross-reactive  staining of 
mouse class II was seen in cells from non-transgenic litter- 
mates (unshaded histograms). The expression level of hu-CD4 
(F) and mouse CD4 (E) was comparable, although Hu-CD4 
was expressed by all  cells,  as previously described (22). 
We examined transgene expression in various tissues by 
immunocytochemistry. Fig. 3 shows the expression pattern 
in transgenic thymus which was stained with no first layer 
mAb (top), L243 (middle), or TAL 14.1 (bottom). Staining was 
found in a classical dass II pattern with both antibodies, namely 
a reticular  distribution  in the cortex,  reflecting expression 
on cortical epithelium and a more confluent pattern in the 
medulla, reflecting expression on dendritic cells and a propor- 
tion of epithelial cells. 
T  Cell Responses of Transgenic Mice  to Immunization  with 
Peptide.  We examined T  cell responses to various peptidic 
antigen fragments which have been reported to be recognized 
by T cells in HLA-DR1 positive individuals. We found that 
transgenic  mice could  respond  to  the  307-319  epitope of 
influenza haemagglutinin (32)  while non-transgenic litter- 
mates could not (Fig. 4 a). A recent report in which T  cell 
hybridomas from chimaeric HLA class  II/H-2E  transgenic 
mice were analyzed reached similar condusions (17). Although 
we have found that some H-2E § strains of mice can respond 
to HA 307-319 (data not shown), the only class II molecule 
available to non-transgenic littermates in this study, H-2Aq, 
does not elicit  a  T  cell response to  HA  307-319. 
A  number of studies have sought to identify epitopes of 
MBP recognized by T  cell clones from MS patients. While 
some studies focused on clones restricted via products of the 
disease associated HLA-DRw15 DQw6 haplotype, many other 
HLA types have also been examined since the association is 
not exclusive.  Two groups analyzing responses in HLA-DK1 
positive individuals identified an epitope in the region of MBP 
139-154  as being of possible relevance to disease,  although 
this epitope is also recognized in association with other al- 
leles (18,  19). In view of the desirability of being able to test 
disease-implicated myelin epitopes in HLA transgenic mice 
in which pathogenesis could be followed (for example after 
using HLA-restricted Ix*prides  in the induction of experimental 
allergic encephalomyelitis, we examined the response to MBP 
Figure 3.  Immunohistochemical analysis of transgenic  mouse thymus 
cryosections.  Monoclonal antibodies  were biotinylated and probed with 
streptavidin-horseradish  peroxidase.  (~p) No first layer antibody (brown 
specks are non-specific uptake of streptavidin);  (m/rid/e)  L243; (bottom) TAL 
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Figure  4.  T cell proliferation to 
antigenic peptides in HLA-DR trans- 
genic mice. Responses of popliteal 
lymph node cells were analysed in 
mice which had been immunized 
with (A)  HA  307-319,  (B)  MBP 
139-154,  or  (C)  tetanus  toxoid 
830-843.  Responses in  HLA-DR 
transgenic mice are shown as open 
triangles and in non-transgenic lit- 
termates  as  open  circles.  Results 
are shown  as  the  mean  Acpm 
+_  SE from three mice per group 
assayed  individually.  Background 
counts ofT cells and medium were 
<1,000  cpm. 
139-154 in HLA-DR1 transgenic mice (Fig. 4 b). Transgenic 
mice responded to the peptide while non-transgenic  litter- 
mates did not. We saw no evidence of any neurological dis- 
ease in MBP 139-154 immunized mice (data not shown), there- 
fore disease studies will require the transgene to be expressed 
on a different genetic background as FVB/N mice are resis- 
tant  to induction  of EAE. 
Other peptides which we tested in HLA-DK1 transgenic 
mice either elicited weaker responses or provoked no response 
in either group. Fig. 4 c shows the response to tetanus toxoid 
830-843, an epitope recognized by human T cells from indi- 
viduals of several different HLA-DR types (33). When mice 
were immunized with this peptide both transgenics  and nega- 
tive littermates made relatively low responses, although re- 
sponses were significantly greater in the transgenic group E. 
pertussis toxin 27-39 (34),  a further  epitope which can be 
presented via HLA-DR1 to human  T  cells,  elicited no re- 
sponses from transgenics  or negative littermates  (data not 
shown). 
HLA Restriction of Responses To Peptide.  Although  new 
responses which can be found in HLA transgenic mice but 
not in negative littermates imply HLA restriction of mouse 
T  cells, we confirmed this formally using a panel of human 
or HLA transfected antigen presenting cells (APC).  T  cell 
lines were generated from immunized mice by four rounds 
of in vitro stimulation with irradiated transgenic splenocytes 
and peptide. These lines were then tested against a panel of 
APC. Fig.  5 shows the response of a T  cell line specific for 
HA 307-319: of the 3 human B-LCL that were tested,  the 
DR1 + B-LCL (HOM-2) presents the peptide to the T  cell 
line,  but neither an HLA-mismatched B-LCL (the DKw15 
homozygous line, PGF) nor an HLA-null mutant (KJ2.2.5) 
elicit any response.  Furthermore,  the matched  HLA-DR1 
transfected L cell could present peptide to the line while its 
mock-transfected counterpart  could not. 
Effect of a Human  CD4  Transgene on HLA-restricted  Re- 
sponses.  In view of conflicting data in the literature over the 
necessity for a species-matched MHC class II/CD4 interac- 
tion for T cell responses, we explored this question by crossing 
the HLA-DK1 transgenic line and a transgenic  line expressing 
human Hu-CD4 in which a full-length Hu-CD4 cDNA is 
driven off a mouse class I promoter. Although the CD4 trans- 
gene is expressed at physiological levels on all peripheral lym- 
phocytes (reference 22 and see Fig.  2), we were concerned 
that,  since class I is not expressed at high levels on CD4 + 
CD8 + DP thymocytes, the transgene may not be expressed 
at this stage which would be critical for it  to influence T 
cell development. In fact, when thymocytes were stained for 
mouse CD4 and CDS,  then gated on DP cells to examine 
the Hu-CD4 + population within this gate on a third color, 
it was found that DP thymocytes express the transgene (Fig. 
6).  When  HLA-DR1 +  Hu-CD4 +  transgenic  mice  and 
HLA-DR1 + Hu-CD4-  littermates  were primed with  the 
HA 307-319 peptide, both groups made equally strong re- 
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Figure  5.  Transgenic mouse T 
cell lines against HA 307-319  are 
HLA-DR1  restricted. The T  cell 
line was tested against a panel of 
APC in a 72-h assay. Proliferation 
is shown as the stimulation index 
(S.I.)  of  T  cell+APC+peptide 
divided by T cell +APC where mean 
backgrounds  without  peptide 
ranged from 193 to 1299 for the var- 
ious cell combinations. 
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Figure 6.  Murine  CD4 §  + 
double positive  thymocytes  express 
the Hu-CD4 transgene. Thymo- 
cytes from a Hu-CD4  + transgenic 
mouse or negative  littermate  were 
tightly gated for DP cells as indi- 
cated in the materials and methods 
and then analyzed  on FD3 for Hu- 
CD4 expression  (Leu  3a). The con- 
tour plot on the left shows  staining 
for Mu-CD4 (FL-2)  and CD8 (FL-1) 
used to identify  DP cells. The stip- 
pled histogram shows staining of 
cells from  the non-transgenic  litter- 
mate and the open histogram,  spe- 
cific  staining  in the transgenic  mouse 
using Leu 3a (FI:3). 
sponses to the peptide and no additional effect of the Hu- 
CD4 transgene was evident (Fig.  7). 
TCR Vfl Repertoire Selection in HLA-DR Transgenic Mice. 
We and others have previously shown that in some cases posi- 
tive selection on introduction of a new class II molecule can 
be  detected as gross  expansions  of the T  cell  population 
utilizing a particular V~ family (12). We therefore analyzed 
TCR V~ usage by mesenteric lymph node cells from trans- 
genic mice and negative littermates (Table 1). A number of 
VB mAbs tested gave little staining in transgenic or non- 
transgenic mice indicating either a germline deletion of some 
V~ gene segments in the FVB/N strain or Mtv-mediated 
deletions (data not shown). Of the other TCR mAbs tested, 
VB4 + T cells were greatly increased in HLA-DR transgenic 
mice, the increase being greater in CD4 § than in CD8 § T 
cells. Use of VB13 was also significantly higher in transgenic 
animals.  These are unlikely to be merely compensatory in- 
creases following deletion of some VB families via DR1 and 
Mtv's since a number of other specificities such as V~5.1 and 
V~10 were unchanged. Although we previously shown that 
V/310 + cells are positively selected  in mice carrying H-2E 
or in HLA-DRA transgenic C57BL/10 mice (12), there was 
no effect on VB10 selection in these mice. We then examined 
superantigen-mediated deletion via the human class II mole- 
cule in these mice which carry Mtv's 7, 8,  13 and 17. Pre- 
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Figure 7.  T cell  proliferation  of 
HLA-DR transgenic mice to HA 
307-319 in the presence or absence 
of  Hu-CD4. Responses  of  popliteal 
lymph node cells were analysed  in 
mice which had been immunized 
11 d previously  with HA 307-319. 
Responses in Hu-CD4  + transgenic 
mice are shown as open triangles 
and in  Hu-CD4- littermates as 
open circles. Results are shown as 
the mean Acpm +_ SE from three 
mice pe~ group assayed  individually. 
Background  counts  with T cells and 
medium were <1,000 cpm. 
sumably due to the presence of Mtv 13, transgenic mice show 
a reduction in the percentage of cells bearing VB3 although 
this was only partial. This may imply that HLA-DR1 binds 
Mtv13 poorly. 
Discussion 
The complexities inherent in analyzing the specificity, func- 
tion and relevance to disease of human T cell clones have made 
it an important objective to generate transgenic mice in which 
various components of human responses such as relevant HLA 
molecules and TCR's can be expressed. However, it has been 
unclear until fairly recently whether it would be possible to 
obtain normal function of the human gene products within 
the mouse immune system. The major concerns have been 
the possible  requirement for a species-matched  HLA class 
II/CD4 interaction and the possibility that differences be- 
tween mouse and human TCR variable sequences would pre- 
clude the possibility of  obtaining responses restricted via human 
MHC molecules. 
Considerable progress  has been made in these areas in re- 
cent years, first analyzing single chain HLA class II trans- 
genic lines in which the function of mixed mouse/human 
molecules was studied (8-12),  then double transgenic lines 
in which normal human heterodimers are expressed (13, 14, 
17). We have now extended this analysis to look at triple 
transgenic mice expressing  three human transgenes, DRA, 
DRB, and CD4. The requirement for a species-matched class 
II/CD4 interaction has proved difficult to dissect,  different 
models producing conflicting results.  One of the earliest 
reports of HLA class II transgene function came from Nishi- 
mura and coworkers who showed the acquisition of trans- 
gene-dependent responsiveness to streptococcal cell wall anti- 
gen, although this was inhibited by antibodies to HLA-DQ, 
mouse CD4, and H-2A, raising the possibility of re-presenta- 
tion of antigen via mouse class II (13). It was subsequently 
demonstrated that cells from these HLA-DQ transgenic mice 
could trigger allogeneic  recognition of the xenoantigen by 
non-transgenic mouse T  cells, the response  again being in- 
hibited by antibodies to mouse CD4 (35). These observations 
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CD4 § cells (%)  CD8 § cells (%) 
Transgene  Transgene  Transgene  Transgene 
negative  positive  negative  positive 
V/~3  4.24  +  0.44  2.22  +  0.42  4.16  _+  0.57  2.98  _+  0.60 
V/~4  10.50  _+  0.44  16.30  _+  1.39  7.15  _+  0.42  10.46  _+  1.17 
V/310  6.76  _+  1.24  7.10  +  1.47  1.42  _+ 0.54  0.99  _+ 0.46 
V/313  18.36  _+  0.80  21.91  _+  1.31  8.25  +_  1.79  10.68  _-!- 1.34 
V138.1,2,3  5.69  _+  0.67  6.3  _+  1.42  1.33  _+  0.13  0.90  +  0.33 
VB5.1  0.50  _+  0.38  1.0 _+  1.0  NT  NT 
Data are expressed as mean percentage of five mice _+ SD. 
Values shown in bold type are significant  at/, <0.001. 
NT, not tested. 
as well as the more recent one of inhibition of specific re- 
sponses by anti-mouse CD4 antibody (14) infer a functional 
interaction between human class II molecules and mouse 
CD4. However, in a study using transfectant APC expressing 
mouse/human chimaeric class II molecules and mouse T cell 
clones as responders,  it was shown that there was consider- 
able functional impairment if the [32 domain was switched 
from mouse to human, although this was not absolute since 
stimulation by APC was stronger than seen in experiments 
with CD4 negative mutants (36).  A  recent study showed 
that chimaeric molecules in which the/32 domain of human 
transgenic class II was substituted by mouse H-2E could in- 
teract effectively with mouse T cells, although no compar- 
ison was made with the non-substituted counterpart (17). 
Another study showed that transgenic mice coexpressing 
Hu-CD4 and HLA-DR4 could respond to HA 307-319 in 
a non-mouse-CD4 dependent manner (37).  We have made 
a direct comparison using titration of an HLA-restricted re- 
sponse to peptide in matched transgenic groups which either 
have or lack a species matched CD4/class II interaction. We 
believe that the CD4 transgene we have used, although not 
limited in  its  expression  to  the murine CD4  SP  lineage, 
should have the potential to participate in repertoire selec- 
tion since it is expressed on DP thymocytes. The caveat that 
this transgene, like the other Hu-CD4 constructs which have 
been used to date, does not carry all of the promoter and 
enhancer sequences involved in directing normal developmental 
control of the gene is an important one when considering 
functional effects. However, a recent study showed that even 
when the Hu-CD4 cDNA was expressed from a CD2 cas- 
sette, the presumably disregulated CD4 product was compe- 
tent to rescue TCR positive selection in mice carrying a tar- 
geted disruption of murine CD4 (16). The fact that we saw 
no difference between Hu-CD4 + and Hu-CD4-  littermates 
supports the notion, implied by the similar T cell responses 
in HLA class II transgenic mice in separate studies with or 
without matched CD4 (14, 17), that for some responses  at 
least the requirement may not be absolute. It may be neces- 
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sary to examine responses after weaker priming or to antigens 
which elicit less potent responses to identify a stronger human 
CD4 dependence. It is noteworthy that in mutagenesis studies 
done to map the interaction site between human class I and 
CD8, mutations which abrogated this binding had little effect 
at the bulk population level and were only seen to prevent 
function at the level of selected clones (38).  An analogous 
effect may be operating here such that in bulk responses the 
proliferation of  clones which are not markedly CD4-dependent 
masks the lack of response  in others. 
A  key application of HLA class II transgenic mice is in 
the analysis of HLA-associated autoimmune disease. While 
we have a relatively clear understanding of the molecular in- 
teractions between TCR, MHC, and peptide which lead to 
specific T cell activation in experimental disease models such 
as experimental allergic encephalomyelitis (39),  there are no 
human autoimmune diseases where each of these components 
has been elucidated in a way which would allow therapeutic 
intervention. In many diseases the best available handle is the 
genetic association  with particular HLA class II alleles, al- 
though whether this reflects a simple immune response gene 
effect in antigen presentation of autoantigen or some more 
complex mechanism is not clear  (40).  Furthermore, it has 
proved impossible to identify unequivocal autoantigenic epi- 
topes of pathogenic T  cells. Among the many obstacles to 
this goal have been the immunogenetic heterogeneity making 
difficult the study of T cell responses in human disease groups. 
When considering the fact that for many autoantigens both 
patients and controls often respond to the same self-epitopes, 
there is no criterion for identifying a cell which is function- 
ally capable of mediating pathology compared to one which 
is not. HLA transgenic mice may help in each of these areas 
since individual HLA alleles can be examined in isolation and 
clones (which could be either HLA-restricted mouse clones 
against autoantigenic peptides or human T cell clones trans- 
ferred to transgenic mice or Hu-SCID HLA transgenic mice) 
can be tested using in vivo models of pathogenesis. Of the 
reported T  cell responses  to MBP by MS patients and con- trols,  there is  considerable variation in  the findings,  some 
groups identifying rather limited patterns of epitope recog- 
nition and TCR usage in diseased individuals (41, 42, 43), 
while others have found enormous heterogeneity (18,  44). 
We noted however that  various studies found responses to 
an MBP epitope in the region of 139-154  in HLA-DR1 + 
patients (18, 19). As a first step towards building "humanized" 
disease models in HLA transgenic mice we asked whether 
HLA-DR1  transgenic mice acquired responsiveness to this 
epitope. It is conserved between the MBP sequences of humans 
and mice except for a conservative valine for alanine substitu- 
tion at 147. We obtained T  cell responses to this epitope in 
transgenic mice but not  in non-transgenic controls;  as yet 
we have seen no HLA transgene-dependent autoimmune dis- 
ease in immunized mice. We are currently conducting a wider 
study utilizing transgenic lines expressing various disease as- 
sociated alleles in the hope of making further progress in this 
area. 
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